Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 14/20 | 0.47 |
| ▸ | DNM1 | Q05193 | 3/20 | 0.37 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.36 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL841874 | 0.98 | KCNH2 (0.50) | KCNH2DNM1PLA2G1BPLA2G2AKDM5A | |
| SCHEMBL842083 | 0.93 | KCNH2 (0.42) | KCNH2PLA2G1BPLA2G2AKDM5AKDM4C | |
| SCHEMBL13609859 | 0.86 | KCNH2 (0.41) | KCNH2DNM1PLA2G1BPLA2G2AKDM5A | |
| SCHEMBL841870 | 0.85 | TSHR (0.33) | KCNH2 | |
| SCHEMBL25018206 | 0.83 | CA12 (0.34) | KCNH2DNM1KDM5AKDM4C | |
| SCHEMBL841865 | 0.83 | CA12 (0.34) | KCNH2DNM1KDM5AKDM4C | |
| SCHEMBL866725 | 0.83 | KCNH2 (0.31) | KCNH2 | |
| SCHEMBL516406 | 0.83 | KCNH2 (0.54) | KCNH2DNM1PLA2G1BPLA2G2AKDM5A | |
| SCHEMBL15383389 | 0.82 | SIGMAR1 (0.38) | KCNH2KDM5AKDM4CSIGMAR1 | |
| SCHEMBL26455606 | 0.81 | SIGMAR1 (0.40) | KCNH2KDM5AKDM4CSIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150258068-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2015-09-17 | — | — | US | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | KCNH2 3688/4885DNM1 2396/4885PLA2G1B 4511/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | KCNH2 3386/4885DNM1 3264/4885PLA2G1B 2035/4885 |
| US-20150258068-A1 | COMBINATION THERAPIES | HDAC1, HDAC8, HDAC5 | KCNH2 4347/4885DNM1 2751/4885PLA2G1B 4546/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.